ਹੌਡਕਿਨ ਲਿੰਫੋਮਾ

The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; PFT is a te…

Sponsor: Takeda
NCT06831370 on ClinicalTrials.gov
Last updated on the registry 23 Feb 2026 · read by us 20 Oct 2026